Collaboration
UK-based nanoTherics Ltd and US-based NanoBioMagnetics Inc have entered into a global cross-license agreement that provides their respective organisations with access to new business opportunities outside their respective geographies.
The companies are pioneering the use of magnetically responsive nanoparticles for a range of life science research and human health applications, including diagnostics and targeted drug delivery systems, and say their technologies are synergistic.
nanoTherics Ltd was formed in August 2007 to exploit a novel gene transfection technology arising from biomedical research conducted at Keele University and the University of Florida. The technology uses nanoparticles and magnetic fields to deliver molecules, including DNA, into living cells.
The company’s recently launched magnefect-nano gene transfection device shows significant improvement in performance over the best non-viral transfection techniques, demonstrating high levels of transfection while maintaining the viability of transfected cells.
NanoBioMagnetics is a nanobiomaterials company pioneering organ-assisting-device technologies, which employ magnetically responsive nanoparticles to cause or drive a desired physiological event when activated by an external magnetic field.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
